PortalPublikationenAdoptive transfer of autologous, HER2-specific, cytotoxic T ...

Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer.

Standard

Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. / Bernhard, Helga; Neudorfer, Julia; Gebhard, Kerstin; Conrad, Heinke; Hermann, Christine; Nährig, Jörg; Fend, Falko; Weber, Wolfgang; Busch, Dirk H; Peschel, Christian.

in: CANCER IMMUNOL IMMUN, Jahrgang 57, Nr. 2, 2, 2008, S. 271-280.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Bernhard, H, Neudorfer, J, Gebhard, K, Conrad, H, Hermann, C, Nährig, J, Fend, F, Weber, W, Busch, DH & Peschel, C 2008, 'Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer.', CANCER IMMUNOL IMMUN, Jg. 57, Nr. 2, 2, S. 271-280. <http://www.ncbi.nlm.nih.gov/pubmed/17646988?dopt=Citation>

APA

Bernhard, H., Neudorfer, J., Gebhard, K., Conrad, H., Hermann, C., Nährig, J., Fend, F., Weber, W., Busch, D. H., & Peschel, C. (2008). Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. CANCER IMMUNOL IMMUN, 57(2), 271-280. [2]. http://www.ncbi.nlm.nih.gov/pubmed/17646988?dopt=Citation

Vancouver

Bernhard H, Neudorfer J, Gebhard K, Conrad H, Hermann C, Nährig J et al. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. CANCER IMMUNOL IMMUN. 2008;57(2):271-280. 2.

Bibtex

@article{6beb0177be1f48a0bec79b5eb66252d6,
title = "Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer.",
abstract = "The human epidermal growth factor receptor 2 (HER2) has been targeted as a breast cancer-associated antigen by immunotherapeutical approaches based on HER2-directed monoclonal antibodies and cancer vaccines. We describe the adoptive transfer of autologous HER2-specific T-lymphocyte clones to a patient with metastatic HER2-overexpressing breast cancer. The HLA/multimer-based monitoring of the transferred T lymphocytes revealed that the T cells rapidly disappeared from the peripheral blood. The imaging studies indicated that the T cells accumulated in the bone marrow (BM) and migrated to the liver, but were unable to penetrate into the solid metastases. The disseminated tumor cells in the BM disappeared after the completion of adoptive T-cell therapy. This study suggests the therapeutic potential for HER2-specific T cells for eliminating disseminated HER2-positive tumor cells and proposes the combination of T cell-based therapies with strategies targeting the tumor stroma to improve T-cell infiltration into solid tumors.",
author = "Helga Bernhard and Julia Neudorfer and Kerstin Gebhard and Heinke Conrad and Christine Hermann and J{\"o}rg N{\"a}hrig and Falko Fend and Wolfgang Weber and Busch, {Dirk H} and Christian Peschel",
year = "2008",
language = "Deutsch",
volume = "57",
pages = "271--280",
journal = "CANCER IMMUNOL IMMUN",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "2",

}

RIS

TY - JOUR

T1 - Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer.

AU - Bernhard, Helga

AU - Neudorfer, Julia

AU - Gebhard, Kerstin

AU - Conrad, Heinke

AU - Hermann, Christine

AU - Nährig, Jörg

AU - Fend, Falko

AU - Weber, Wolfgang

AU - Busch, Dirk H

AU - Peschel, Christian

PY - 2008

Y1 - 2008

N2 - The human epidermal growth factor receptor 2 (HER2) has been targeted as a breast cancer-associated antigen by immunotherapeutical approaches based on HER2-directed monoclonal antibodies and cancer vaccines. We describe the adoptive transfer of autologous HER2-specific T-lymphocyte clones to a patient with metastatic HER2-overexpressing breast cancer. The HLA/multimer-based monitoring of the transferred T lymphocytes revealed that the T cells rapidly disappeared from the peripheral blood. The imaging studies indicated that the T cells accumulated in the bone marrow (BM) and migrated to the liver, but were unable to penetrate into the solid metastases. The disseminated tumor cells in the BM disappeared after the completion of adoptive T-cell therapy. This study suggests the therapeutic potential for HER2-specific T cells for eliminating disseminated HER2-positive tumor cells and proposes the combination of T cell-based therapies with strategies targeting the tumor stroma to improve T-cell infiltration into solid tumors.

AB - The human epidermal growth factor receptor 2 (HER2) has been targeted as a breast cancer-associated antigen by immunotherapeutical approaches based on HER2-directed monoclonal antibodies and cancer vaccines. We describe the adoptive transfer of autologous HER2-specific T-lymphocyte clones to a patient with metastatic HER2-overexpressing breast cancer. The HLA/multimer-based monitoring of the transferred T lymphocytes revealed that the T cells rapidly disappeared from the peripheral blood. The imaging studies indicated that the T cells accumulated in the bone marrow (BM) and migrated to the liver, but were unable to penetrate into the solid metastases. The disseminated tumor cells in the BM disappeared after the completion of adoptive T-cell therapy. This study suggests the therapeutic potential for HER2-specific T cells for eliminating disseminated HER2-positive tumor cells and proposes the combination of T cell-based therapies with strategies targeting the tumor stroma to improve T-cell infiltration into solid tumors.

M3 - SCORING: Zeitschriftenaufsatz

VL - 57

SP - 271

EP - 280

JO - CANCER IMMUNOL IMMUN

JF - CANCER IMMUNOL IMMUN

SN - 0340-7004

IS - 2

M1 - 2

ER -